ArticleFrontiers in pharmacology2025
Clinical application of combined anticoagulation therapy in anti-MDA5 antibody-positive associated interstitial lung disease-a retrospective study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the clinical efficacy of combined anticoagulation therapy in patients with anti-Melanoma Differentiation-Associated protein 5 (MDA5) antibody-positive associated interstitial lung disease. Methods: A retrospective cohort study was conducted, which included 100 patients diagnosed with anti-MDA5 antibody-positive interstitial lung disease at our hospital between January 2022 and December 2024. Based on the treatment approach, the patients were divided into two groups: the combined anticoagulation group (receiving conventional therapy plus sequential low-molecular-weight heparin followed by rivaroxaban) and the control group (receiving conventional therapy only). Comparisons were made between the two groups regarding pulmonary function parameters (FVC%, DLCO%, PaO Results: At 4-week treatment and 3-month follow-up, the combined anticoagulation group had superior Forced Vital Capacity (FVC)%, Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)%, and Arterial Partial Pressure of Oxygen (PaO Conclusion: Combined anticoagulation therapy improves pulmonary function, reduces inflammation, and lowers complication and exacerbation risks in anti-MDA5 antibody-positive interstitial lung disease patients. With notable clinical value, it offers a new treatment strategy for this refractory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.